CMCharles Robert Marshall

Charles Robert Marshall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles Robert Marshall has a total of 321 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex shapes plasma molecular signatures of dementia risk across APOE ε4 strata

    by Sara Calhas, Yue Liu, Sheena Waters, Dorsa Abdolkarimi, Cristina Legido-Quigley, Oleg Blyuss, Charles R Marshall, Petroula Proitsi

    Sex and APOE ε4 influence dementia risk, but whether its molecular predictors differ across sex and APOE ε4 strata remains unclear. We investigated plasma proteomic and metabolomic signatures predicting future dementia in 43,759 UK Biobank participants across four sex-by-APOE ε4 groups. The association between APOE ε4 carrier status and dementia differed by sex (interaction p = 0.027). Machine-learning models achieved higher discrimination in APOE ε4 carriers (AUC 0.85-0.90) than non-carriers (AUC 0.74-0.76), with the highest performance in female carriers. Most top molecular predictors were subgroup-specific, including C7, CDON and EDIL3 in female carriers and KLK4, MMP12 and TGFBI in male carriers. When UK Biobank models were applied to the Global Neurodegeneration Proteomics Consortium, 12/17 available top predictors in female carriers and 10/16 in male carriers remained highly ranked. These findings identify distinct molecular signatures of dementia risk across sex and APOE ε4 strata, supporting stratified biomarker discovery.

  • Open Access

    Voices from the Field: Chilean Health Professionals’ Practices and Perspectives on Dementia Risk Reduction in People with Memory Concerns

    by Rosario Isabel Espinoza-Jeraldo, Claudia Miranda-Castillo, Charles R Marshall, Claudia Cooper

    The Chilean national dementia plan prioritises prevention. People with Mild Cognitive Impairment (MCI) and subjective cognitive complaints (SCCs) are at increased dementia risk and may benefit from secondary prevention programmes addressing modifiable risk factors. We aimed to explore how Chilean health and social care professionals support older people with these conditions, and where they perceive gaps in current secondary dementia prevention activities. We co-designed an online mixed-methods survey responding to our aims and then purposively recruited health and care professionals working with people with cognitive concerns from diverse roles and geographical regions across Chile to complete it. We mapped findings to the Consolidated Framework for Implementation Research, identifying meta-inferences in a convergent analysis. A total of 110 professionals (31.8% women) completed the survey. Of those providing diagnostic services, half frequently diagnosed patients with MCI (42.4%, n = 25/59) or SCCs (54.2%, n = 32/59) at least once a week. In the overall sample, most professionals were likely to explain that MCI increased dementia risk (79.1%, n = 87/110), and around half did so for SCCs (54.5%, n = 60/110). Some were more likely to discuss risk reduction if they perceived patients as capable, resourceful and motivated to make lifestyle changes. Meta-inferences highlighted that successful secondary risk reduction requires multimodal, flexible, evidence-based design, adequate physical infrastructure, suitably trained staff, funding, and a wider consideration of socioeconomic and health inequalities. Current professional practice in delivering dementia prevention advice may unintentionally reinforce inequalities. National prevention strategies should address structural inequalities to reach those most likely to benefit. People with memory concerns are a heterogenous group; framing their management as dementia prevention may not be appropriate for all cases.

  • Open Access

    Prevalence and Clinical Determinants of Cognitive Impairment in Diverse Patients with Parkinson Disease

    by Alexandra Zirra, Kamalesh C Dey, Ellen Camboe, Essa Bhadra, Rhiannon Laban, Brook Huxford, Shafaq Hussain-Ali, Cristina C Simonet, Caroline Budu, David A Gallagher, et al.

    Importance: The real-world prevalence and the clinical determinants associated with cognitive impairment in diverse patients with Parkinson disease (PD) have been understudied. Objective: To determine the prevalence of cognitive impairment in a diverse PD cohort and explore associations with vascular, motor, and nonmotor factors. Design, setting and participants: Case-only analysis of diverse patients with PD recruited to the East London Parkinson disease project (July 2022 to July 2025) at the Royal London Hospital, a tertiary referral center. Of 237 patients with cognitive status defined by expert, multi-disciplinary, clinical consensus, 223 remained after excluding atypical or secondary parkinsonism, other dementias, and study withdrawal. Exposures: Observational study (no experimental intervention); exposures included vascular risk factors, motor and nonmotor clinical features. Main Outcome(s) and Measure(s): The main outcome was cognitive impairment (PDCI), defined as mild cognitive impairment (PDMCI) or dementia (PDD) by expert clinical consensus based on clinical, imaging, and cognitive screening. Results: Among 223 participants with a median disease duration of 4.0 (1.0-9.0) years, 112 (50.2%) had PDCI, including 62 (27.8%) with PDD and 50 (22.4%) with PDMCI. South Asian ethnicity was associated with PDCI in univariate analysis (OR, 2.30; 95% CI, 1.32-4.00, P = .003) and the association strengthened after adjusting for age, gender, years of education, disease duration and depression scores (OR, 3.60; 95% CI, 1.68-7.69, P < .001). PDCI was associated with increased odds of smoking (OR, 3.62; 95% CI, 1.56-8.41, P = .003) in the adjusted model. Increased odds were also associated with motor severity (Movement Disorders Society Unified Parkinson Disease Rating Scale Part III; OR per point increase 1.07; 95% CI, 1.04-1.10; P < .001), and daytime somnolence score (Epworth Sleepiness Scale; OR per point increase, 1.08; 95% CI, 1.01-1.16; P = .03). Conclusions and Relevance: In this multi-ethnic study of PD using gold-standard expert multidisciplinary consensus, cognitive impairment was common and more prevalent among South Asian individuals. Smoking, greater motor severity, and higher daytime somnolence were associated with increased odds of cognitive impairment.

  • Open Access

    The contribution of apolipoprotein E genetic variation to dementia risk in British South Asians

    by Benjamin M Jacobs, Avinash Chandra, Isabelle Francesca Foote, Faiza Durrani, Sheena Waters, Yue Liu, Petroula Proitsi, Cara L Croft, Dylan M Williams, Sarah Finer, et al.

    Understanding the genetic basis of dementia in diverse populations is essential to ensure that efforts to predict, prevent, and treat dementia are equitable. The strongest genetic risk factor for dementia - APOE genotype - has not been assessed in population-scale cohorts of South Asian ancestry. To test whether APOE variation is associated with all-cause dementia in British South Asians, we analysed data from 51,104 volunteers Genes & Health study - a cohort study of British Bangladeshi and British Pakistani individuals who have undergone genotyping and consented for lifelong (England & Wales National Health Service) linkage to healthcare records. All-cause dementia was defined using electronic healthcare records. APOE genotypes were defined using phased, imputed genotype data. Cox proportional hazards models were used to assess the relationship between APOE genotype and dementia. Population attributable fractions were calculated for each APOE genotype. Phenome-wide association tests were performed to determine the impact of APOE genotype on a range of traits and disease. We identified 614 cases of dementia and 50,490 controls without any dementia diagnostic codes. Dementia cases (n = 614, of which 451 [73.5%] were incident) were recruited at an older age (median 71.3 vs 39.0), were more likely to be male (58.6% vs 44.5%), and were more likely to carry at least one APOE ε4 allele (26.4% vs 19.6%) than controls without dementia (n = 50,490). The APOE ε4 allele was associated with all-cause dementia in a dose-dependent fashion (APOE ε4/ε4: Hazard Ratio [HR] 2.7, 95% CI 1.7 - 4.2, P < 0.0001; APOE ε4/ε3: Hazard Ratio [HR] 1.5, 95% CI 1.2 - 1.8, P < 0.001; Cox multivariable regression models adjusted for age at recruitment, gender, genetic principal components 1 - 10, and genetic ancestry; all models used APOE ε3/ε3 as reference). The overall proportion of all-cause dementia cases which could be attributed to this allele was 12.9% (95% CI -5.9% - 25.5%). APOE ε4 was also associated with elevated triglycerides and Low Density Lipoprotein (LDL) cholesterol. APOE ε4 - the major genetic risk factor for sporadic dementia in European-ancestry populations - has a similar impact on dementia risk in British South Asians. Prediction and prevention studies aiming to use APOE to identify people at high risk of dementia should be inclusive of all ancestries. Genetic analysis of dementia risk in diverse populations is essential for ensuring that the downstream benefits - for prediction, prevention, and drug discovery - are shared equitably.

  • Open Access

    Circulating inflammatory proteins predict dementia risk, and are linked to structural brain changes and modifiable risk factors

    by Dorsa Abdolkarimi, Yue Liu, Lachlan Gilchrist, Sara Calhas, Sheena Waters, Charles R. Marshall, Petroula Proitsi

    Introduction: Systemic inflammation has been identified as a key factor in neurodegeneration but the value of circulating inflammatory proteins in dementia risk prediction and their causal role has not been elucidated. Methods: We leveraged proteomic data from 43,685 UK Biobank participants to investigate associations between 728 Olink inflammatory proteins and incident dementia using Cox proportional-hazards (Cox-PH) models. We used Cox-PH with LASSO regularisation to calculate a sparse signature of inflammatory proteins (ProSig) predicting incident dementia. Linear regressions assessed the association between ProSig and individual proteins with brain image-derived phenotypes and Brain Age in participants with available neuroimaging data ( n = 4,106). Formal mediation analyses investigated whether inflammatory proteins mediated associations between genetic and modifiable risk factors and dementia outcomes. Mendelian randomisation (MR) tested the causal relationship between inflammatory proteins and dementia outcomes. Results: 218 inflammatory proteins were individually associated with incident dementia in Cox-PH models ( p FDR < 0.05). A 20-protein signature significantly improved the prediction of incident dementia beyond known risk factors. TNFRSF11B, a protein linked to vascular damage, was associated with both incident dementia and reduced hippocampal volume. Two proteins, sFRP4 and MEPE, were linked to reduced Brain Age, with sFRP4 also being protective against dementia. Mediation analyses indicated that TNFRSF11B, APOE and C7 may partially mediate associations between modifiable risk factors and dementia. MR analyses suggested protective causal effects of TNFSF13 and IL17D. Conclusions: By triangulating evidence, this study shows that inflammatory proteins improve dementia risk prediction and play heterogeneous roles in dementia pathophysiology.


  • Top Cited Papers

    The Nottingham consensus on dementia risk reduction policy: recommendations from a modified Delphi process

    by Harriet Demnitz-King, Sube Banerjee, Claudia Cooper, Charlotte Kenten, Rosemary Phillips, Sedigheh Zabihi, Yvonne Birks, Carol Brayne, Sallyann Browning, Camille Carroll, et al.

    Translation of evidence about dementia risk and its reduction into effective, equitable public health policy is a major challenge. To address this challenge, the National Institute for Health and Care Research Policy Research Unit in Dementia and Neurodegeneration at Queen Mary University of London (DeNPRU-QM) convened a multidisciplinary panel of 40 experts from across England, with diverse lived, academic, clinical, policy and advocacy experience, at various career stages, and of diverse gender and ethnicity, to develop actionable policy recommendations for dementia risk reduction. Through a 2-day in-person workshop and a subsequent three-round modified Delphi survey, the panel evaluated and refined statements on dementia prevention. The panel achieved consensus on 56 recommendations in four domains: public health messaging, individual-level interventions, population-level interventions and research commissioning. A key priority across all domains was the need to consider and address health inequalities so that prevention efforts do not exacerbate existing disparities. Our recommendations provide policymakers with a robust foundation for designing and implementing an evidence-based dementia prevention strategy in England and provide guidance that can inform approaches in other countries and contexts. By prioritizing clear communication, targeted intervention and sustained research investment, the recommendations can help to address structural inequities and advance dementia risk reduction. Ongoing cross-sector advocacy will be crucial in driving policy adoption and implementation.


  • Open Access

    The contribution of Apoliproprotein E genetic variation to dementia risk in British South Asians

    by Benjamin M Jacobs, Avinash Chandra, Arnab Mandal, Isabelle Foote, Faiza Durrani, Sheena Waters, Yue Liu, Petroula Proitsi, Cara L. Croft, Dylan M Williams, et al.

    INTRODUCTION: Understanding the genetic basis of dementia in diverse populations is essential to ensure that efforts to predict, prevent, and treat dementia are equitable. The strongest genetic risk factor for dementia - APOE genotype - has not been assessed in population-scale cohorts of South Asian ancestry. METHODS: We analysed data from 51,104 volunteers in the Genes & Health study - a cohort study of British South Asians - who have undergone genotyping and consented for linkage to healthcare records. All-cause dementia was defined using electronic healthcare records. APOE genotypes were defined using phased, imputed genotype data. Cox proportional hazards models were used to assess the relationship between APOE genotype and dementia. Population attributable fractions were calculated for each APOE genotype. RESULTS: APOE ε 4 was associated with all-cause dementia in a dose-dependent fashion (Case N = 614, Control N = 50,490; APOE ε 4/ ε 4: Hazard Ratio 2.7, P < 0.0001; APOE ε 4/ ε 3: Hazard Ratio 1.5, P < 0.001). The overall proportion of dementia cases attributable to this allele was 14.2% (95% CI -2.8% - 25.0%). APOE ε 4 was also associated with elevated triglycerides and Low Density Lipoprotein (LDL) cholesterol. DISCUSSION: APOE ε 4 - the major genetic risk factor for sporadic dementia in European-ancestry populations - has a similar impact on dementia risk in British South Asians.


  • Open Access

    The relationship between neuropsychiatric dimensions and markers of Parkinson's disease risk in the UK Biobank

    by Bahaaeddin Attaallah, Sheena Waters, Charles Marshall, Alastair Noyce

    Neuropsychiatric symptoms are a significant yet often overlooked aspect of Parkinson's disease (PD). Using UK Biobank data, we examined associations between neuropsychiatric dimensions and PD risk markers. Factor analysis identified four dimensions—Depression, Anxiety, Stress-Adversity, and Alcoholism/Addiction—across three groups: PD, healthy controls, cerebrovascular disease (CVD) as neurological controls. These dimensions showed distinct patterns in PD. Depression scores were significantly elevated, while Alcoholism/Addiction scores were consistently lower. Neuroimaging linked Alcoholism/Addiction to subcortical changes specific to PD, particularly quantitative susceptibility mapping in the substantia nigra, consistent with the dopaminergic system's role in goal-directed behaviour. GBA1 carrier status was linked to age-related changes in this dimension. Furthermore, PD patients with higher Alcoholism/Addiction showed greater volatility in cognitive and motor function, with worsening before diagnosis and subsequent improvement. These findings highlight the complex interplay between psychiatric symptoms, neurobiological changes, and genetic factors in PD, suggesting that specific neuropsychiatric profiles may serve as early indicators of disease risk and progression

  • Open Access

    Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption

    by Jonathan M. Schott, Charles R. Marshall

    The licensing of lecanemab and donanemab, disease-modifying immunotherapies for Alzheimer's disease (AD) targeting β-amyloid pathology, has been met with difference in opinion about efficacy, adverse effects, and cost-effectiveness. Here we summarize the current situation and make the case for cautious adoption of these treatments into clinical practice. This opinion is predicated on four main observations: 1) these treatments impact the core pathologies of AD and result in meaningful benefits; 2) while adverse effects can be serious, these are proving manageable in clinical practice; 3) upscaling services to deliver these agents is likely to provide wider benefits for diagnosing and treating dementia and facilitating the adoption of future treatments from the dementia drug pipeline; and 4) factoring in both the wider societal cost of care and potential for continued accrual of long term benefits will be likely to bring these treatments within acceptable cost-effectiveness thresholds.


  • Open Access

    Early presentations of dementia in a diverse population

    by Sedigheh Zabihi, Jonathan P Bestwick, Mark Jitlal, Phazha Lk Bothongo, Qiqi Zhang, Christine Carter, Moïse Roche, Sarah Morgan‐Trimmer, Yvonne Birks, Mark Wilberforce, et al.

    INTRODUCTION: Improved recognition of non‐cognitive presentations of dementia could reduce inequalities in dementia diagnosis, particularly if sociocultural factors influence help‐seeking for cognitive symptoms. METHODS: We conducted a nested case‐control study using electronic healthcare records from primary care practices in East London, United Kingdom, to assess associations between prediagnostic presentations to primary care and subsequent dementia diagnosis. RESULTS: We included 4137 individuals with a dementia diagnosis and 15,754 controls in the matched analysis. In addition to memory difficulties, a range of symptoms were more common in the decade before diagnosis, including depression, anxiety, use of antipsychotics, insomnia, constipation, incontinence, hypotension, hearing loss, imbalance, and dizziness. DISCUSSION: A range of non‐cognitive presentations are seen during the prodromal period of dementia in a diverse population. Improved recognition of these associations and their variation by ethnicity could increase access to dementia diagnosis through improved recognition of early features in people from different sociocultural backgrounds. Highlights: Prediagnostic signs of dementia include cognitive and non‐cognitive symptoms. Psychiatric symptoms are common up to a decade prior to a dementia diagnosis. Autonomic prediagnostic symptoms are more common among South Asian groups. The importance of prediagnostic symptoms of dementia varies by ethnicity.